Abstract:SUMMARYMetabolic syndrome (MetS) is a diagnostic category which identifies subjects at high risk for diabetes and cardiovascular diseases, erectile dysfunction (ED) and male hypogonadism. However, MetS impact on male infertility has been poorly studied. We systematically evaluated possible associations between MetS and clinical characteristics in men with couple infertility. Out of 367 consecutive subjects, 351 men without genetic abnormalities were studied. MetS was defined according to the International Diab… Show more
“…We may speculate that several factors might account for these differences. Emphasis on obesity when defining MetS (such as the case of Lotti et al 22. using the International Diabetes Federation worldwide definition) and older age (as observed in our secondary infertile patients) might unveil the impact of MetS on seminal parameters whereas younger age and NCEP-ATP III definition, as observed in our sample of primary infertile men, would not 34…”
Section: Discussionmentioning
confidence: 73%
“…We found that tT was reduced in +MetS patients compared to the –MetS group whereas cfT did not seem to be affected by this condition. In contrast, Lotti et al 22. reported decreased values of both tT and fT, while Leisegang et al 23.…”
Section: Discussionmentioning
confidence: 91%
“…To this regard, the relationship between MetS and seminal parameters remains controversial. Indeed, two observational studies2223 have shown an association between MetS and poor sperm parameters in men broadly presenting for couple infertility. Conversely, our previous findings regarding primary infertile men reported no noticeable detrimental effect induced by MetS 34.…”
Section: Discussionmentioning
confidence: 99%
“…Although MetS was shown to have a detrimental effect on male reproductive health2223 in primary infertile men, the impact of MetS on male reproductive function has never been analyzed before in White-European men seeking medical help for secondary infertility. Likewise, the lack of previous clinical evidence and the increasing prevalence of MetS,24 with its potential impact on both the hormonal milieu and the overall health status of men, prompted us to investigate the role of MetS in male secondary infertility, assessing (i) the prevalence of MetS, (ii) correlations between MetS and clinical characteristics, and (iii) the impact of MetS on semen and hormonal parameters in a cohort of White-European men presenting for secondary couple's infertility.…”
We aimed to determine the impact of metabolic syndrome (MetS) on reproductive function in men with secondary infertility, a condition that has received relatively little attention from researchers. Complete demographic, clinical, and laboratory data from 167 consecutive secondary infertile men were analyzed. Health-significant comorbidities were scored with the Charlson Comorbidity Index (CCI; categorised 0 vs 1 vs 2 or higher). NCEP-ATP III criteria were used to define MetS. Semen analysis values were assessed based on the 2010 World Health Organization (WHO) reference criteria. Descriptive statistics and logistic regression models tested the association between semen parameters and clinical characteristics and MetS. MetS was found in 20 (12%) of 167 men. Patients with MetS were older (P < 0.001) and had a greater BMI (P < 0.001) compared with those without MetS. MetS patients had lower levels of total testosterone (P = 0.001), sex hormone-binding globulin, inhibin B, and anti-Müllerian hormone (all P ≤ 0.03), and they were hypogonadal at a higher prevalence (P = 0.01) than patients without MetS. Moreover, MetS patients presented lower values of semen volume, sperm concentration, and sperm normal morphology (all P ≤ 0.03). At multivariate logistic regression analysis, no parameters predicted sperm concentration, normal sperm morphology, and total progressive motility. Our data show that almost 1 of 8 White-European men presenting for secondary couple's infertility is diagnosed with MetS. MetS was found to be associated with a higher prevalence of hypogonadism, decreased semen volume, decreased sperm concentration, and normal morphology in a specific cohort of White-European men.
“…We may speculate that several factors might account for these differences. Emphasis on obesity when defining MetS (such as the case of Lotti et al 22. using the International Diabetes Federation worldwide definition) and older age (as observed in our secondary infertile patients) might unveil the impact of MetS on seminal parameters whereas younger age and NCEP-ATP III definition, as observed in our sample of primary infertile men, would not 34…”
Section: Discussionmentioning
confidence: 73%
“…We found that tT was reduced in +MetS patients compared to the –MetS group whereas cfT did not seem to be affected by this condition. In contrast, Lotti et al 22. reported decreased values of both tT and fT, while Leisegang et al 23.…”
Section: Discussionmentioning
confidence: 91%
“…To this regard, the relationship between MetS and seminal parameters remains controversial. Indeed, two observational studies2223 have shown an association between MetS and poor sperm parameters in men broadly presenting for couple infertility. Conversely, our previous findings regarding primary infertile men reported no noticeable detrimental effect induced by MetS 34.…”
Section: Discussionmentioning
confidence: 99%
“…Although MetS was shown to have a detrimental effect on male reproductive health2223 in primary infertile men, the impact of MetS on male reproductive function has never been analyzed before in White-European men seeking medical help for secondary infertility. Likewise, the lack of previous clinical evidence and the increasing prevalence of MetS,24 with its potential impact on both the hormonal milieu and the overall health status of men, prompted us to investigate the role of MetS in male secondary infertility, assessing (i) the prevalence of MetS, (ii) correlations between MetS and clinical characteristics, and (iii) the impact of MetS on semen and hormonal parameters in a cohort of White-European men presenting for secondary couple's infertility.…”
We aimed to determine the impact of metabolic syndrome (MetS) on reproductive function in men with secondary infertility, a condition that has received relatively little attention from researchers. Complete demographic, clinical, and laboratory data from 167 consecutive secondary infertile men were analyzed. Health-significant comorbidities were scored with the Charlson Comorbidity Index (CCI; categorised 0 vs 1 vs 2 or higher). NCEP-ATP III criteria were used to define MetS. Semen analysis values were assessed based on the 2010 World Health Organization (WHO) reference criteria. Descriptive statistics and logistic regression models tested the association between semen parameters and clinical characteristics and MetS. MetS was found in 20 (12%) of 167 men. Patients with MetS were older (P < 0.001) and had a greater BMI (P < 0.001) compared with those without MetS. MetS patients had lower levels of total testosterone (P = 0.001), sex hormone-binding globulin, inhibin B, and anti-Müllerian hormone (all P ≤ 0.03), and they were hypogonadal at a higher prevalence (P = 0.01) than patients without MetS. Moreover, MetS patients presented lower values of semen volume, sperm concentration, and sperm normal morphology (all P ≤ 0.03). At multivariate logistic regression analysis, no parameters predicted sperm concentration, normal sperm morphology, and total progressive motility. Our data show that almost 1 of 8 White-European men presenting for secondary couple's infertility is diagnosed with MetS. MetS was found to be associated with a higher prevalence of hypogonadism, decreased semen volume, decreased sperm concentration, and normal morphology in a specific cohort of White-European men.
“…Standardized protocols with axial and transverse examinations of the lesions were performed (Oyen, 2002, Bhatt et al ., 2006; American Institute of Ultrasound in M edicine et al . 2011; Lotti et al ., 2013). Two experienced sonographers (A.M.I.…”
SummaryThe purpose of this study was to evaluate prospectively the accuracy of qualitative and strain ratio elastography (SE) in the differential diagnosis of non‐palpable testicular lesions. The local review board approved the protocol and all patients gave their consent. One hundred and six patients with non‐palpable testicular lesions were consecutively enrolled. Baseline ultrasonography (US) and SE were correlated with clinical and histological features and ROC curves developed for diagnostic accuracy. The non‐palpable lesions were all ≤1.5 cm; 37/106 (34.9%) were malignant, 38 (35.9%) were benign, and 31 (29.2%) were non‐neoplastic. Independent risk factors for malignancy were as follows: size (OR 17.788; p = 0.002), microlithiasis (OR 17.673, p < 0.001), intralesional vascularization (OR 9.207, p = 0.006), and hypoechogenicity (OR, 11.509, p = 0.036). Baseline US had 89.2% sensitivity (95% CI 74.6–97.0) and 85.5% specificity (95% CI 75.0–92.8) in identifying malignancies, and 94.6% sensitivity (95% CI 86.9–98.5) and 87.1% specificity (95% CI 70.2–96.4) in discriminating neoplasms from non‐neoplastic lesions. An elasticity score (ES) of 3 out of 3 (ES3, maximum hardness) was recorded in 30/37 (81.1%) malignant lesions (p < 0.001). An intermediate score of 2 (ES2) was recorded in 19/38 (36.8%) benign neoplastic lesions and in 22/31 (71%) non‐neoplastic lesions (p = 0.005 and p = 0.001 vs. malignancies). None of the non‐neoplastic lesions scored ES3. Logistic regression analysis revealed a significant association between ES3 and malignancy (χ2 = 42.212, p < 0.001). ES1 and ES2 were predictors of benignity (p < 0.01). Overall, SE was 81.8% sensitive (95% CI 64.8–92.0) and 79.1% specific (95% CI 68.3–88.4) in identifying malignancies, and 58.6% sensitive (95% CI 46.7–69.9) and 100% specific (95% CI 88.8–100) in discriminating non‐neoplastic lesions. Strain ratio measurement did not improve the accuracy of qualitative elastography. Strain ratio measurement offers no improvement over elastographic qualitative assessment of testicular lesions; testicular SE may support conventional US in identifying non‐neoplastic lesions when findings are controversial, but its added value in clinical practice remains to be proven.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.